---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Generic, brand name and therapeutic class of product. Topics: Manufacturer: IDEAYA Biosciences; Nonproprietary name and development codes; Therapeutic class of darovasertib as described by the company; Combination partner: crizotinib (XALKORI), a kinase inhibitor marketed by Pfizer. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: IDEAYA Biosciences

> “IDEAYA retains regulatory and commercial rights to darovasertib in the United States, while Servier holds all such rights outside the United States.”

Source: [IDEAYA Biosciences press release, OptimUM-11 first patient dosed (2026)](https://media.ideayabio.com/2026-09-09-IDEAYA-Biosciences-and-Servier-Announce-First-Patient-Dosed-in-OptimUM-11-Global-Phase-3-Registrational-Trial-of-Darovasertib-and-Crizotinib-as-Adjuvant-Therapy-for-Subjects-with-Uveal-Melanoma)

> “The Company owns or controls all commercial rights in its darovasertib program in UM in the United States, including in mUM and in primary UM, subject to certain economic obligations pursuant to its exclusive, worldwide license to darovasertib with Novartis.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

<a id="topic-2.1.2.1-2"></a>

### Nonproprietary name and development codes

> “The Company renamed Novartis’ LXS196 oncology asset as IDE196, which has a non-proprietary name of darovasertib.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

| Substance record field | Quoted record |
| --- | --- |
| Preferred substance name | “DAROVASERTIB” |
| United States Adopted Name | “DAROVASERTIB [USAN]” |
| International Nonproprietary Name | “darovasertib [INN]” |
| WHO Drug Dictionary name | “Darovasertib [WHO-DD]” |
| Development code synonyms | “IDE196”; “LXS196”; “NVP-LXS-196” |
| Molecular formula | “C22H23F3N8O” |

Source: [FDA UNII record E0YF0M8O09](https://precision.fda.gov/uniisearch/srs/unii/E0YF0M8O09)

<a id="topic-2.1.2.1-3"></a>

### Therapeutic class of darovasertib as described by the company

> “Darovasertib is an oral, potent and selective small molecule inhibitor of protein kinase C and our most advanced clinical program.”

Source: [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm)

> “Darovasertib is a potential first-in-class oral, small-molecule inhibitor of PKC.”

Source: [IDEAYA Biosciences press release, OptimUM-11 first patient dosed (2026)](https://media.ideayabio.com/2026-09-09-IDEAYA-Biosciences-and-Servier-Announce-First-Patient-Dosed-in-OptimUM-11-Global-Phase-3-Registrational-Trial-of-Darovasertib-and-Crizotinib-as-Adjuvant-Therapy-for-Subjects-with-Uveal-Melanoma)

<a id="topic-2.1.2.1-4"></a>

### Brand name of darovasertib

No evidence found.

<a id="topic-2.1.2.1-5"></a>

### Combination partner: crizotinib (XALKORI), a kinase inhibitor marketed by Pfizer

> “XALKORI® (crizotinib) capsules, for oral use”
> “XALKORI® (crizotinib) oral pellets”
> “Initial U.S. Approval: 2011”

Source: [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
